Diagnosis and management of high platelet reactivity on treatment with clopidogrel

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 7, 2012, Pages 645-651

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

acute coronary syndromes; clopidogrel; P2Y12; prasugrel; ticagrelor

Indexed keywords

CLOPIDOGREL; TICLOPIDINE;

ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; LABORATORY TEST; PLATELET REACTIVITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT RESPONSE;

BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84872102569     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1326785     Document Type: Article

References (53)

1. 12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood: 2011; 117 7 2102 2112
2. Bonello L., Tantry U. S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol: 2010; 56 12 919 933
3. Bouman H. J., Schömig E., van Werkum J. W., et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med: 2011; 17 1 110 116
4. Hulot J. S., Collet J. P., Cayla G., et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv: 2011; 4 5 422 428
5. Camps J., Joven J., Mackness B., et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med: 2011; 17 9 1041 1042, author reply 1042-1044
6. Dansette P. M., Rosi J., Bertho G., Mansuy D. Paraoxonase-1 and clopidogrel efficacy. Nat Med: 2011; 17 9 1040 1041, author reply 1042-1044
7. Cuisset T., Morange P. E., Quilici J., Bonnet J. L., Gachet C., Alessi M. C. Paraoxonase-1 and clopidogrel efficacy. Nat Med: 2011; 17 9 1039, author reply 1042-1044
8. Fontana P., James R., Barazer I., et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost: 2011; 9 8 1664 1666
9. Trenk D., Hochholzer W., Fromm M. F., et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet: 2011; 4 4 429 436
10. Sibbing D., Koch W., Massberg S., et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J: 2011; 32 13 1605 1613
11. Cattaneo M. New P2Y(12) inhibitors. Circulation: 2010; 121 1 171 179
12. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol: 2004; 24 11 1980 1987
13. Brar S. S., ten Berg J., Marcucci R., et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol: 2011; 58 19 1945 1954
14. Cattaneo M. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost: 2012; 10 3 327 336
15. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost: 2007; 5 Suppl 1 230 237
16. Cuisset T., Frere C., Poyet R., et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis: 2010; 103 1 39 45
17. Lordkipanidzé M., Pharand C., Nguyen T. A., Schampaert E., Palisaitis D. A., Diodati J. G. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J: 2008; 29 2877 2885
18. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C. W. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost: 2009; 101 2 333 339
19. Paniccia R., Antonucci E., Gori A. M., et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost: 2007; 5 9 1839 1847
20. Paniccia R., Antonucci E., Maggini N., et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost: 2010; 104 2 287 292
21. Breet N. J., van Werkum J. W., Bouman H. J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA: 2010; 303 8 754 762
22. Madsen E. H., Saw J., Kristensen S. R., Schmidt E. B., Pittendreigh C., Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem: 2010; 56 5 839 847
23. von Beckerath N., Sibbing D., Jawansky S., et al. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. Blood Coagul Fibrinolysis: 2010; 21 1 46 52
24. Gaglia M. A., Torguson R., Pakala R., et al. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol: 2011; 24 6 529 534
25. Duxbury B. M., Poller L. The oral anticoagulant saga: past, present, and future. Clin Appl Thromb Hemost: 2001; 7 4 269 275
26. Cattaneo M., Hayward C. P., Moffat K. A., Pugliano M. T., Liu Y., Michelson A. D. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost: 2009; 7 6 1029
27. Campo G., Fileti L., de Cesare N., et al. 3T/2R Investigators Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol: 2010; 56 18 1447 1455
28. Arméro S., Camoin-Jau L., Omar Aït Mokhtar O., et al. Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets: 2010; 21 7 503 507
29. Jaitner J., Stegherr J., Morath T., et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost: 2011; 105 1 107 112
30. Aleil B., Jacquemin L., De Poli F., et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv: 2008; 1 6 631 638
31. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol: 2011; 57 25 2474 2483
32. Tofler G. H., Brezinski D., Schafer A. I., et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med: 1987; 316 24 1514 1518
33. Kozinski M., Bielis L., Wisniewska-Szmyt J., et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets: 2011; 22 8 579 587
34. Mehran R., Pocock S. J., Nikolsky E., et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol: 2010; 55 23 2556 2566
35. Eikelboom J. W., Mehta S. R., Anand S. S., Xie C., Fox K. A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation: 2006; 114 8 774 782
36. Pocock S. J., Mehran R., Clayton T. C., et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation: 2010; 121 1 43 51
37. Sibbing D., Steinhubl S. R., Schulz S., Schömig A., Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol: 2010; 56 4 317 318
38. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol: 2008; 51 14 1404 1411
39. Bonello L., Camoin-Jau L., Armero S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol: 2009; 103 1 5 10
40. Pena A., Collet J. P., Hulot J. S., et al. Can we override clopidogrel resistance? Circulation: 2009; 119 21 2854 2857
41. Price M. J., Berger P. B., Teirstein P. S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA: 2011; 305 11 1097 1105
42. Gurbel P. A., Tantry U. S. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA: 2011; 305 11 1136 1137
43. Price M. J., Angiolillo D. J., Teirstein P. S., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation: 2011; 124 10 1132 1137
44. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA: 2011; 306 11 1215 1223
45. Trenk D., Stone G. W., Gawaz M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary Intervention with implantation of Drug-Eluting Stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel). Study. J Am Coll Cardiol: 2012; 59 24 2159 2164
46. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm (accessed Aug 3, 2010)
47. Holmes D. R. Jr, Dehmer G. J., Kaul S., Leifer D., O'Gara P. T., Stein C. M. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warningo": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol: 2010; 56 4 321 341
48. Hochholzer W., Trenk D., Fromm M. F., et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol: 2010; 55 22 2427 2434
49. Shuldiner A. R., O'Connell J. R., Bliden K. P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA: 2009; 302 8 849 857
50. Bouman H. J., Harmsze A. M., van Werkum J. W., et al. Variability in on-treatment platelet reactivity explained by CYP2C19 2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart: 2011; 97 15 1239 1244
51. Aleil B., Léon C., Cazenave J. P., Gachet C. CYP2C19 2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. J Thromb Haemost: 2009; 7 10 1747 1749
52. Mega J. L., Hochholzer W., Frelinger A. L. III., et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA: 2011; 306 20 2221 2228
53. Roberts J. D., Wells G. A., Le May M. R., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet: 2012; 379 9827 1705 1711